Cargando…
What the Intensivists Need to Know About Critically Ill Myeloma Patients
Multiple myeloma (MM) is a hematological malignancy characterized by an increase in aberrant plasma cells in the bone marrow leading to rising monoclonal protein in serum and urine. With the introduction of novel therapies with manageable side effects, this incurable disease has evolved into a chron...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121630/ http://dx.doi.org/10.1007/978-3-319-74588-6_98 |
_version_ | 1783515244942852096 |
---|---|
author | Nair, Ranjit Patel, Krina |
author_facet | Nair, Ranjit Patel, Krina |
author_sort | Nair, Ranjit |
collection | PubMed |
description | Multiple myeloma (MM) is a hematological malignancy characterized by an increase in aberrant plasma cells in the bone marrow leading to rising monoclonal protein in serum and urine. With the introduction of novel therapies with manageable side effects, this incurable disease has evolved into a chronic disease with an acceptable quality of life for the majority of patients. Accordingly, management of acute complications is fundamental in reducing the morbidity and mortality in MM. MM emergencies include symptoms and signs related directly to the disease and/or to the treatment; many organs may be involved including, but not limited to, renal, cardiovascular, neurologic, hematologic, and infectious complications. This review will focus on the numerous approaches that are aimed at managing these complications. |
format | Online Article Text |
id | pubmed-7121630 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71216302020-04-06 What the Intensivists Need to Know About Critically Ill Myeloma Patients Nair, Ranjit Patel, Krina Oncologic Critical Care Article Multiple myeloma (MM) is a hematological malignancy characterized by an increase in aberrant plasma cells in the bone marrow leading to rising monoclonal protein in serum and urine. With the introduction of novel therapies with manageable side effects, this incurable disease has evolved into a chronic disease with an acceptable quality of life for the majority of patients. Accordingly, management of acute complications is fundamental in reducing the morbidity and mortality in MM. MM emergencies include symptoms and signs related directly to the disease and/or to the treatment; many organs may be involved including, but not limited to, renal, cardiovascular, neurologic, hematologic, and infectious complications. This review will focus on the numerous approaches that are aimed at managing these complications. 2019-07-09 /pmc/articles/PMC7121630/ http://dx.doi.org/10.1007/978-3-319-74588-6_98 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Nair, Ranjit Patel, Krina What the Intensivists Need to Know About Critically Ill Myeloma Patients |
title | What the Intensivists Need to Know About Critically Ill Myeloma Patients |
title_full | What the Intensivists Need to Know About Critically Ill Myeloma Patients |
title_fullStr | What the Intensivists Need to Know About Critically Ill Myeloma Patients |
title_full_unstemmed | What the Intensivists Need to Know About Critically Ill Myeloma Patients |
title_short | What the Intensivists Need to Know About Critically Ill Myeloma Patients |
title_sort | what the intensivists need to know about critically ill myeloma patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121630/ http://dx.doi.org/10.1007/978-3-319-74588-6_98 |
work_keys_str_mv | AT nairranjit whattheintensivistsneedtoknowaboutcriticallyillmyelomapatients AT patelkrina whattheintensivistsneedtoknowaboutcriticallyillmyelomapatients |